Trial Profile
A Randomized Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Bladder cancer
- Focus Pharmacodynamics
- 17 Mar 2021 Status changed from active, no longer recruiting to completed.
- 28 Apr 2020 Planned End Date changed from 1 Sep 2021 to 1 Dec 2021.
- 30 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Sep 2021.